tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Gain Therapeutics (GANX)
NASDAQ:GANX
US Market
GANX
Gain Therapeutics
RESEARCH TOOLSreports

Gain Therapeutics (GANX) Stock News & Sentiment

Compare
411 Followers
Buy Rating on Gain Therapeutics Driven by Validated Mechanism, Compelling Phase 1b Parkinson’s Data, and Attractive Risk‑Reward Despite Near‑Term Financing Needs
Premium
Ratings
Buy Rating on Gain Therapeutics Driven by Validated Mechanism, Compelling Phase 1b Parkinson’s Data, and Attractive Risk‑Reward Despite Near‑Term Financing Needs
11d ago
GANX
Maintaining Buy on Gain Therapeutics: Strong GCase Biology, Validated GluSph Biomarker, and Favorable Risk-Reward for GT-02287 in Parkinson’s Disease
Premium
Ratings
Maintaining Buy on Gain Therapeutics: Strong GCase Biology, Validated GluSph Biomarker, and Favorable Risk-Reward for GT-02287 in Parkinson’s Disease
11d ago
GANX
Gain Therapeutics: Attractive Upside on GT-02287 Parkinson’s Data and Upcoming KOL Catalyst Supports Buy Rating
Premium
Ratings
Gain Therapeutics: Attractive Upside on GT-02287 Parkinson’s Data and Upcoming KOL Catalyst Supports Buy Rating
18d ago
GANX
Clinical and Mechanistic De-Risking of GT-02287 Underpins Buy Rating on Gain Therapeutics (GANX)
Premium
Ratings
Clinical and Mechanistic De-Risking of GT-02287 Underpins Buy Rating on Gain Therapeutics (GANX)
1M ago
GANX
Reiterating Buy on Gain Therapeutics: Promising GT-02287 Biomarker Data and Efficient Clinical Path Support Disease‑Modifying Potential in Parkinson’s
Premium
Ratings
Reiterating Buy on Gain Therapeutics: Promising GT-02287 Biomarker Data and Efficient Clinical Path Support Disease‑Modifying Potential in Parkinson’s
1M ago
GANX
Gain Therapeutics Reports Encouraging Phase 1b Parkinson’s Data
Premium
Company Announcements
Gain Therapeutics Reports Encouraging Phase 1b Parkinson’s Data
1M ago
8K
GANX
Buy Rating for Gain Therapeutics Driven by Promising GT-02287 Developments and Upcoming Clinical Data
Premium
Ratings
Buy Rating for Gain Therapeutics Driven by Promising GT-02287 Developments and Upcoming Clinical Data
2M ago
GANX
More GANX News >

GANX News on the Web

Why Gain Therapeutics, Inc.’s (GANX) Stock Is Down 6.51%
AAII
Neutral
Why Gain Therapeutics, Inc.’s (GANX) Stock Is Down 5.03%
AAII
Neutral
Why Gain Therapeutics, Inc.’s (GANX) Stock Is Up 5.84%
AAII
Neutral
Why Gain Therapeutics, Inc.’s (GANX) Stock Is Up 7.37%
AAII
Neutral
Gain Therapeutics (GANX) Upgraded to Buy: Here's Why
Zacks
Bullish
Why Gain Therapeutics, Inc.’s (GANX) Stock Is Up 9.74%
AAII
Neutral
Gain Therapeutics’ KOL Event Highlights GT-02287’s Disease-Modifying Promise in Parkinson’s—Key Phase 1b Biomarker Results in Focus
Market Chameleon
Neutral
Why Gain Therapeutics, Inc.’s (GANX) Stock Is Up 16.89%
AAII
Neutral

News Score - Last 7 Days

Neutral
GANX
Sector Average
Media Buzz
This Week1 articles
Weekly Average1.5 articles
News Sentiment
This Week50%
Sector Average57%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is GANX’s Media Buzz Sentiment?
1 articles about GANX were published this week. In an average week, 1.5 articles are published.
    What is GANX’s weekly average amount of articles?
    In an average week, 1.5 articles about GANX are published.
      What is GANX’s News Sentiment?
      50% of articles about GANX were positive this week, compared to its sector average of 57%.
        Healthcare Stocks that are Trending in the News
        CAHCardinal Health
        ALKSAlkermes
        WSTWest Pharmaceutical Services
        AGENAgenus
        PENPenumbra
        Showing the stocks with the most bullish news sentiment over the past week